Retatrutide: The Triple-Agonist Peptide Explained

In the rapidly evolving landscape of incretin-based metabolic therapies, retatrutide stands alone. It is the first — and currently only — molecule to simultaneously activate three hormone receptors: GLP-1, GIP, and glucagon. And its early clinical data has stunned researchers.

Developed by Eli Lilly under the research designation LY3437943, retatrutide produced the largest weight loss ever documented in a registrational-pathway obesity trial at the time of its Phase 2 publication: 24.2% mean body weight reduction over 48 weeks.¹ This guide breaks down what makes retatrutide unique, how it compares to existing dual-agonists like tirzepatide, and what the Phase 3 program means for the future of obesity pharmacotherapy.

The Triple Receptor Mechanism

Understanding retatrutide requires understanding how each of its three target receptors contributes to metabolic regulation independently — and what happens when all three are activated simultaneously.

GLP-1 Receptor: Appetite & Glucose Control

The GLP-1 (glucagon-like peptide-1) component mirrors the mechanism seen in semaglutide and tirzepatide. GLP-1 receptor activation delays gastric emptying, enhances glucose-dependent insulin secretion, and suppresses appetite via central hypothalamic signaling. This is the primary driver of reduced caloric intake.²

GIP Receptor: Lipid Metabolism & Beta-Cell Support

Glucose-dependent insulinotropic polypeptide (GIP) receptor agonism, shared with tirzepatide, enhances insulin secretion through a pathway complementary to GLP-1. Critically, GIP signaling has been linked to improved lipid handling in adipose tissue and may contribute to the distribution of weight loss (favoring fat mass over lean mass).³

Glucagon Receptor: The Thermogenic Differentiator

This is what makes retatrutide fundamentally different. Glucagon receptor activation directly stimulates hepatic lipid oxidation (fat burning in the liver), increases energy expenditure through thermogenesis, and promotes amino acid catabolism. In isolation, glucagon would raise blood glucose — but when combined with GLP-1/GIP agonism, the glycemic effects are counterbalanced while the metabolic benefits (fat oxidation, energy expenditure) are preserved.⁴

In summary: GLP-1 reduces intake, GIP optimizes lipid handling, and glucagon burns stored energy. It's a three-pronged metabolic attack.

Phase 2 Trial Data: Record-Breaking Results

The Phase 2 dose-finding trial, published in the New England Journal of Medicine in June 2023, enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.¹

Results at 48 weeks across dose groups:

• 1 mg: -8.7% mean body weight reduction
• 4 mg: -17.1% mean body weight reduction
• 8 mg: -22.8% mean body weight reduction
• 12 mg: -24.2% mean body weight reduction
• Placebo: -2.1% mean body weight reduction

At the 12 mg dose, 26% of participants lost more than 30% of their body weight — a threshold previously considered near-surgical territory. No prior pharmacotherapy had come close to these figures in a non-surgical population.¹

Importantly, the weight loss trajectory at 48 weeks had not yet plateaued in the higher-dose groups, suggesting that longer treatment durations could yield even greater reductions.

Retatrutide vs Tirzepatide: A Framework Comparison

A critical differentiator is retatrutide's impact on hepatic steatosis (fatty liver disease). In the Phase 2 trial, participants with non-alcoholic fatty liver disease (NAFLD) showed mean liver fat reductions exceeding 80% — suggesting retatrutide could become a first-in-class treatment for NASH/MAFLD, a condition with no currently approved pharmacotherapy.⁵

Phase 3: The TRIUMPH Program

Eli Lilly has enrolled patients across multiple Phase 3 trials under the TRIUMPH umbrella:

• TRIUMPH-1: Retatrutide vs placebo in adults with obesity (BMI ≥30)
• TRIUMPH-2: Retatrutide vs placebo in adults with T2D and obesity
• TRIUMPH-3: Retatrutide for MASH (metabolic dysfunction-associated steatohepatitis)
• TRIUMPH-4: Cardiovascular outcomes trial

Initial Phase 3 readouts are anticipated in late 2026. If the TRIUMPH data confirms the Phase 2 results, retatrutide could receive FDA priority review designation, potentially reaching the market by 2027-2028.⁶

Safety & Side Effect Profile

For researchers sourcing these compounds, Amino Club provides COA-verified peptides with documented purity testing. Browse peptides →

The Phase 2 side effect profile was broadly consistent with the GLP-1 agonist class. The most common treatment-emergent adverse events at the 12 mg dose were:

• Nausea: 45.8%
• Diarrhea: 25.0%
• Vomiting: 20.8%
• Constipation: 14.6%
• Decreased appetite: 25.0%

GI events were most common during the dose-escalation period and generally resolved with continued treatment. No pancreatitis or medullary thyroid carcinoma events were observed. The glucagon component raised theoretical concerns about hepatotoxicity, but liver enzyme elevations were generally mild and transient.¹

Sources

1. Jastreboff, A.M., Kaplan, L.M., et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine, 2023; 389(6): 514-526.
2. Drucker, D.J. "GLP-1 receptor agonists and the cardiovascular system." Nature Reviews Cardiology, 2024.
3. Samms, R.J., Coghlan, M.P., Sloop, K.W. "How May GIP Enhance the Therapeutic Efficacy of GLP-1?" Trends in Endocrinology & Metabolism, 2020; 31(6): 410-421.
4. Day, J.W., et al. "A new glucagon and GLP-1 co-agonist eliminates obesity in rodents." Nature Chemical Biology, 2009; 5: 749-757.
5. Hartman, M.L., et al. "Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis." Diabetes Care, 2020.
6. Eli Lilly and Company. "Lilly Initiates TRIUMPH Phase 3 Clinical Program for Retatrutide." Press release, 2024.